clinical stage pharmaceutical company.
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the Armed Forces Radiobiology Research Institute (AFRRI). Humanetics began working with AFRRI to test an array of drug candidates using their highly developed capabilities. From this program, BIO 300 emerged as a lead candidate and the underlying technology was in-licensed from AFRRI to Humanetics. In the ensuing years, the Company has progressed this program into multiple clinical uses with a primary focus on improving treatment of solid tumor cancers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 2, 2021 | Grant | — | 1 | Regenerative Medicine Minnesota | — | Detail |
Apr 12, 2018 | Grant | $5.40M | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Regenerative Medicine Minnesota | Yes | Grant |
National Institutes of Health | Yes | Grant |